Business Wire

Marrakech Investor Day: International Investors are Choosing Marrakech, One of the World’s Dream Destinations

7.4.2022 12:28:00 EEST | Business Wire | Press release

Share

In collaboration with the International Finance Corporation (IFC) and the Swiss State Secretariat for Economic Affairs (SECO), the Marrakech-Safi Regional Center for Investment hosted the inaugural edition of the Marrakech Investor Day, a meaningful event designed to allow hundreds of investors to explore the fantastic advantages and new investment opportunities across Marrakech.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005464/en/

Global supply chain disruptions, recent geopolitical changes, and the “Green Production” requirement, coupled with the multiple free trade agreements that provide direct access to more than 1.3 billion consumers, have aptly positioned Marrakech as the sustainable alternative for investors around the world.

Marrakech is a captivating imperial city boasting a sub-tropical mild climate and beautiful landscapes that make it an unmissable tourist destination. Moreover, Morocco provides attractive advantages for investors from all over the world. These advantages include political stability, a geo-strategic location and direct access to Europe and Africa’s markets, an attractive business-friendly environment, a robust, modern infrastructure, and prestigious talents taught in two of Africa’s best universities, all combined with a unique lifestyle and improved quality of life.

Marrakech, a city at the forefront of sustainability

Driven by the unrelenting will of the King of Morocco, with a target to generate 52% of energy from renewable sources by 2030, Marrakech offers investors the opportunity to put a little “green” in their portfolios and decarbonize the world’s industries.

The event was also an opportunity to explore the cultural richness and diversity of Marrakech, which actively encourages and facilitates foreign investments in multiple sectors, such as the agribusiness, tourism, creative industries, renewable energy, logistics, offshoring, and ICT.

These investment opportunities were made possible thanks to multiple reforms and facilitation mechanisms, which offer several incentives to stimulate investment (up to 30% of the total investment amount), improve the business climate and the competitiveness of the private sector.

More than 50 non-double taxation agreements, the absence of restrictions in the percentage of share capital and the free repatriation of funds are also influential factors that enable the region to offer a particularly modern and attractive legal and fiscal environment.

As part of the Marrakech Investor Day’s events, international investors were given a first-hand demonstration of these advantages that promote ease of doing investments in Marrakech and enhance transparency, such as the dematerialization of customs procedures and the personalized support of the Marrakech-Safi Regional Center for Investment.

The event also featured a panel discussion on the data-related investment opportunities, followed by the Marrakech Investor Awards ceremony, designed to celebrate the regions’ key investors.

To relive the event, and learn more about investment opportunities in Marrakech, visit www.marrakechinvest.ma

About:

The Regional Investment Center of Marrakech-Safi is a public institution with a mission is to facilitate, support and promote investments in the Marrakech-Safi region.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hanaa Zouzaf
h.zouzaf@crimarrakech.ma

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye